↓ Skip to main content

Primary hepatic neuroendocrine carcinoma: report of two cases and literature review

Overview of attention for article published in BMC Clinical Pathology, March 2018
Altmetric Badge

About this Attention Score

  • Among the highest-scoring outputs from this source (#50 of 114)
  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Primary hepatic neuroendocrine carcinoma: report of two cases and literature review
Published in
BMC Clinical Pathology, March 2018
DOI 10.1186/s12907-018-0070-7
Pubmed ID
Authors

Zi-Ming Zhao, Jin Wang, Ugochukwu C. Ugwuowo, Liming Wang, Jeffrey P. Townsend

Abstract

Primary hepatic neuroendocrine carcinoma (PHNEC) is extremely rare. The diagnosis of PHNEC remains challenging-partly due to its rarity, and partly due to its lack of unique clinical features. Available treatment options for PHNEC include surgical resection of the liver tumor(s), radiotherapy, liver transplant, transcatheter arterial chemoembolization (TACE), and administration of somatostatin analogues. We report two male PHNEC cases and discuss the diagnosis and treatment options. Both cases presented with abdominal pain; case two also presented with symptoms of jaundice. The initial diagnosis for both cases was poorly differentiated grade 3 small-cell neuroendocrine carcinoma, based on imaging characteristics and the pathology of liver biopsies. Final diagnoses of PHNEC were arrived at by ruling out non-hepatic origins. Case one presented with a large tumor in the right liver lobe, and the patient was treated with TACE. Case two presented with tumors in both liver lobes, invasions into the left branch of hepatic portal vein, and metastasis in the hepatic hilar lymph node. This patient was ineligible for TACE and was allergic to the somatostatin analogue octreotide. This limited treatment options to supportive therapies such as albumin supplementation for liver protection. Patient one and two died at 61 and 109 days, respectively, following initial hospital admission. We diagnosed both cases with poorly differentiated grade 3 small-cell PHNEC through imaging characteristics, immunohistochemical staining of liver biopsies, and examinations to eliminate non-hepatic origins. Neither TACE nor liver protection appeared to significantly extend survival time of the two patients, suggesting these treatments may be inadequate to improve survival of patients with poorly differentiated grade 3 small-cell PHNEC. The prognosis of poorly differentiated grade 3 small-cell PHNEC is poor due to limited and ineffective treatment options.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 4 17%
Student > Doctoral Student 3 13%
Professor > Associate Professor 3 13%
Student > Postgraduate 3 13%
Other 2 8%
Other 4 17%
Unknown 5 21%
Readers by discipline Count As %
Medicine and Dentistry 15 63%
Computer Science 1 4%
Agricultural and Biological Sciences 1 4%
Social Sciences 1 4%
Veterinary Science and Veterinary Medicine 1 4%
Other 0 0%
Unknown 5 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 March 2020.
All research outputs
#11,240,914
of 17,367,552 outputs
Outputs from BMC Clinical Pathology
#50
of 114 outputs
Outputs of similar age
#172,481
of 283,900 outputs
Outputs of similar age from BMC Clinical Pathology
#1
of 1 outputs
Altmetric has tracked 17,367,552 research outputs across all sources so far. This one is in the 23rd percentile – i.e., 23% of other outputs scored the same or lower than it.
So far Altmetric has tracked 114 research outputs from this source. They receive a mean Attention Score of 3.5. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 283,900 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them